Screener
Charles River Laboratories CRL Selling, general and administrative — Asset Impairments and Other Costs
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:OtherRestructuringCosts.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Three Months Ended | June 27, 2026 / Severance and Transition Costs | June 27, 2026 / Asset Impairments and Other Costs | June 27, 2026 / Total | June 28, 2025 / Severance and Transition Costs | June 28, 2025 / Asset Impairments and Other Costs | June 28, 2025 / Total |
|---|---|---|---|---|---|---|
| Cost of services provided (excluding amortization of intangible assets) | $1,436 | $13,699 | $15,135 | $(1,308) | $26,451 | $25,143 |
| Cost of products sold (excluding amortization of intangible assets) | (24) | 528 | 504 | (95) | 1,425 | 1,330 |
| Selling, general and administrative | 841 | 6,577 | 7,418 | 5,130 | 597 | 5,727 |
| Total restructuring costs | $2,253 | $20,804 | $23,057 | $3,727 | $28,473 | $32,200 |
| Six Months Ended | ||||||
| Cost of services provided (excluding amortization of intangible assets) | $6,227 | $34,893 | $41,120 | $6,390 | $39,624 | $46,014 |
| Cost of products sold (excluding amortization of intangible assets) | 1,175 | 1,719 | 2,894 | 168 | 2,658 | 2,826 |
| Selling, general and administrative | 1,069 | 9,554 | 10,623 | 5,583 | 1,622 | 7,205 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's selling, general and administrative — asset impairments and other costs?
- Charles River Laboratories (CRL) reported selling, general and administrative — asset impairments and other costs of $6.58M in Q2 2026.
- How has Charles River Laboratories's selling, general and administrative — asset impairments and other costs changed year-over-year?
- Charles River Laboratories's selling, general and administrative — asset impairments and other costs increased by 1001.7% year-over-year, from $597K to $6.58M.
- What is the long-term trend for Charles River Laboratories's selling, general and administrative — asset impairments and other costs?
- Over 3 years (2022 to 2025), Charles River Laboratories's selling, general and administrative — asset impairments and other costs has grown at a 83.2% compound annual growth rate (CAGR), from $763K to $4.69M.
- What does selling, general and administrative — asset impairments and other costs mean?
- This metric tracks non-cash charges related to the write-down of intangible or tangible assets, alongside miscellaneous non-recurring administrative expenses. It reflects the accounting recognition that the carrying value of certain assets within the administrative segment exceeds their recoverable amount. Monitoring these costs helps investors identify potential issues with capital allocation or the long-term viability of administrative infrastructure investments.
Ask your AI about Charles River Laboratories's selling, general and administrative — asset impairments and other costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude